Epithalon vs Rapamycin
A side-by-side research comparison of Epithalon and Rapamycin across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Epithalon | Rapamycin |
|---|---|---|
| Full name | Epithalon (Epitalon / Epithalone) | Rapamycin (Sirolimus) |
| Category | Anti-Aging | Anti-Aging |
| Status | Research compound | FDA-approved (off-label for longevity) |
| Mechanism | Activates telomerase reverse transcriptase (hTERT) expression for telomere maintenance. Also normalizes circadian rhythm via melatonin regulation and modulates antioxidant enzymes. | Inhibits mTOR complex 1 (mTORC1), reducing cellular growth signaling and activating autophagy - the cellular recycling process. Mimics caloric restriction at the molecular level. |
| Molecular weight | 390.4 Da | 914.17 Da |
| Half-life | 3-4 hours | ~62 hours |
| Bioavailability | High (SubQ) | ~14% oral |
| Typical dose | 5-10 mg | 3-6 mg |
| Frequency | Daily for 10-20 days | Once weekly |
| Route | Subcutaneous injection | Oral tablet |
Epithalon reported benefits
- Telomerase activation
- Telomere lengthening
- Melatonin normalization
- Improved sleep patterns
- Antioxidant enzyme upregulation
- Potential lifespan extension
Rapamycin reported benefits
- Enhanced autophagy
- Immune rejuvenation
- Anti-aging cellular effects
- Cancer risk reduction
- Improved vaccine response (elderly)
- Longevity extension
Related comparisons
Research and educational reference only. Not medical advice.